论文部分内容阅读
目的:探讨琥珀酸索利那新与盐酸坦索罗辛在Ⅲ型前列腺炎患者中的联合应用价值。方法:选取我院2013年1~12月期间所收治的118例Ⅲ型前列腺炎患者作为本次临床研究对象,随机分为研究组59例和对照组59例。对照组患者采用盐酸坦索罗辛缓释胶囊的临床药物治疗方案,研究组患者则在对照组的基础之上加用琥珀酸索利那新片的联合药物治疗方案,并分别对研究组和对照组的临床治疗效果、慢性前列腺炎症状指数、前列腺液炎症因子表达等情况进行比较和分析。结果:研究组患者的临床治愈率和总有效率分别为49.15%(29/59)和96.61%(57/59),均显著高于对照组患者的32.20%(19/59)和74.58%(44/59),差异均有统计学意义(χ2=3.51、11.61,P<0.05);研究组患者治疗后的疼痛或不适症状评分、排尿症状评分、生活质量评分、总体评分分别为(6.12±2.35)分、(4.12±1.73)分、(4.34±1.81)分、(15.47±4.15)分,均明显低于对照组患者的(9.57±2.83)分、(5.98±2.41)分、(6.72±2.66)分、(21.92±4.48)分,差异均有统计学意义(t=7.34、5.03、5.80、8.16,P<0.05);研究组患者治疗后的前列腺液IL-8、IL-10、TNF-α值分别为(2 584.13±591.87)pg/ml、(243.89±86.75)pg/ml、(28.28±13.83)pg/ml,均明显优于对照组患者的(3 357.25±743.36)pg/ml、(189.17±74.43)pg/ml、(40.67±15.75)pg/ml,差异均有统计学意义(t=6.25、3.68、4.56,P<0.05)。结论:琥珀酸索利那新联合盐酸坦索罗辛对Ⅲ型前列腺炎患者临床治疗效果的提升、相关临床症状和炎症因子水平的改善均有极其重要的促进作用,可作为Ⅲ型前列腺炎患者较为优化的联合用药方案,向临床推广应用。
Objective: To investigate the combined application of solifenacin succinate and tamsulosin hydrochloride in type Ⅲ prostatitis patients. Methods: A total of 118 patients with type Ⅲ prostatitis admitted in our hospital from January to December 2013 were selected as the clinical study subjects. They were randomly divided into study group (59 cases) and control group (59 cases). Patients in the control group were treated with tamsulosin hydrochloride sustained-release capsules. Patients in the study group were given a combination drug regimen of solifenacin succinate on the basis of the control group, and the study groups and control groups Group clinical efficacy, chronic prostatitis symptom index, expression of prostatic fluid inflammatory cytokines were compared and analyzed. Results: The clinical cure rate and total effective rate in study group were 49.15% (29/59) and 96.61% (57/59), respectively, which were significantly higher than those in control group (32.20% (19/59) and 74.58% (Χ2 = 3.51,11.61, P <0.05). The scores of pain or discomfort, urination symptom score, quality of life score and overall score after treatment in the study group were (6.12 ± (4.12 ± 1.73) points, (4.34 ± 1.81) points and (15.47 ± 4.15) points in the control group were significantly lower than those in the control group (9.57 ± 2.83), (5.98 ± 2.41), (6.72 ± 2.66) and (21.92 ± 4.48) points respectively, the difference was statistically significant (t = 7.34,5.03,5.80,8.16, P <0.05). The levels of IL-8, IL- -α values were significantly higher than that of the control group (3 357.25 ± 743.36) pg / ml (2 584.13 ± 591.87) pg / ml, (243.89 ± 86.75) pg / ml and (28.28 ± 13.83) pg / ml respectively , (189.17 ± 74.43) pg / ml and (40.67 ± 15.75) pg / ml, respectively. The difference was statistically significant (t = 6.25,3.68,4.56, P <0.05). CONCLUSIONS: Solifenacin succinate combined with tamsulosin hydrochloride has an extremely important effect on improving the clinical therapeutic effect, improving the clinical symptoms and the level of inflammatory cytokines in patients with type Ⅲ prostatitis. It can be used as a type Ⅲ prostatitis The more optimized combination regimen, to the clinical application.